Commercial Revenue came in at the top end of guidance. Revenue Guidance increased. Guidance is more important than EPS any day of the week. Looking forward to post earnings webinar assuming that tradition continues; I’d like to ask about expectations for overall breakeven for all indications and if projections for breakeven of soft tissue and burns indications remains in January of 2025. Still expecting Go approval by EOY. Extra R&D coming due to expanded soft tissue indication that is larger than expected, but that should provide nice returns on the dollar since FDA approval is already achieved. Overall, a fantastic report that should inspire LT confidence.
AVH Chart, page-679
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.74 |
Change
0.250(10.0%) |
Mkt cap ! $170.3M | |||
| Open | High | Low | Value | Volume |
| $2.56 | $2.78 | $2.56 | $2.148M | 794.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 911 | $2.74 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.75 | 7135 | 1 |
View Market Depth
| Last trade - 16.10pm 29/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.76 |
Change
0.250 ( 10.1 %) |
||||
| Open | High | Low | Volume | ||
| $2.59 | $2.78 | $2.59 | 31457 | ||
| Last updated 15.58pm 29/05/2024 ? | |||||
| AVH (ASX) Chart |